Generate Biomedicines (NASDAQ:GENB) Trading 8.4% Higher – Time to Buy?

Posted by Geri Gentry on Sep 17th, 2026

Generate Biomedicines Inc (NASDAQ:GENB – Get Free Report)’s share price shot up 8.4% during mid-day trading on Thursday . The stock traded as high as $16.95 and last traded at $17.00. 145,986 shares changed hands during trading, a decline of 82% from the average daily volume of 796,735 shares. The stock had previously closed at $15.68.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on GENB. Wall Street Zen cut shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a research report on Saturday, September 12th. Weiss Ratings assumed coverage on Generate Biomedicines in a research note on Tuesday, August 11th. They issued a “sell (d)” rating on the stock. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Generate Biomedicines in a research report on Tuesday, September 8th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Generate Biomedicines currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.40.

Read Our Latest Stock Analysis on Generate Biomedicines

Generate Biomedicines Price Performance

The business has a 50 day simple moving average of $15.12. The firm has a market capitalization of $2.20 billion and a price-to-earnings ratio of -10.79.

Generate Biomedicines (NASDAQ:GENB – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The firm had revenue of $6.31 million during the quarter. On average, research analysts predict that Generate Biomedicines Inc will post -2.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company purchased a new stake in Generate Biomedicines during the 2nd quarter valued at $1,431,000. Squarepoint Ops LLC bought a new position in shares of Generate Biomedicines during the second quarter valued at about $530,000. AXQ Capital LP purchased a new stake in shares of Generate Biomedicines during the second quarter worth about $218,000. Braidwell LP bought a new stake in shares of Generate Biomedicines in the second quarter worth about $55,398,000. Finally, Susquehanna International Group LLP purchased a new position in Generate Biomedicines during the 2nd quarter valued at about $196,000.

Generate Biomedicines Company Profile

(Get Free Report)

Generate Biomedicines is a biotechnology company that uses generative artificial intelligence and machine learning to discover and design protein-based medicines. Its technology is intended to model relationships among protein sequences, structures and biological functions, helping researchers create therapeutic proteins with desired characteristics.

The company’s research activities are focused on developing novel biologic medicines for areas of significant unmet medical need, including oncology, immunology, infectious diseases and rare diseases.